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Future Directions in the Use of DNA
Adducts As Internal Dosimeters for
Monitoring Human Exposure to
Environmental Mutagens and Carcinogens
by Curtis C. Harris*
Scientific opportunities generally arise when two or more research areas converge and/or advances in
methodology occur. This occurred at the turn of the 19th century in the field of infectious bacterial and
fungal diseases. As we draw near to the 21st century, research in the laboratory is providing us with both
critical information on mechanisms of carcinogenesis and new technological advancements, including
those in immunology, biochemistry, and molecular biology. Investigations in the field of epidemiology
have clearly demonstrated the importance of environmental exposure to carcinogens and have identified
populations at high cancer risk. It is now practical to integrate laboratory determinations into classic
epidemiological approaches. Several markers, e.g., carcinogen-DNA adducts, related to tumor initiation
and perhaps to tumor conversion, are currently being evaluated. We also need to develop indicators of
tumor promotion and progression. The potential of biochemical and molecular epidemiology to predict
cancer risk in an individual prior to the onset of clinically evident cancer provides an exciting new
opportunity in cancer research and prevention.
Introduction
The topic ofthis conference is a facet of an expanding
area of cancer research-the biochemical and molecular
epidemiology ofcancer(1,2). Thismultidisciplinary area
combines epidemiological and laboratory approaches. Its
primary goal is to identify individuals at high cancer
risk by obtaining evidence of high exposure to carcin-
ogens leading to pathobiological lesions in target cells
and/or increased oncogenic susceptibility due to either
inherited or acquired host factors. Clinical and epide-
miological studies have identified populations at high
cancer risk, and in many cases also the etiological agents,
e.g., tobacco smoke as the major cause of lung cancer
and asbestos as the primary etiological agent for me-
sothelioma. Laboratory studieshaveextendedthese ep-
idemiological findings byidentifyingspecificcarcinogens
found in complex mixtures and have provided us with
a better understanding of the pathogenesis ofthe mul-
tistage carcinogenic process.
The concepts of tumor initiation, promotion, conver-
sion, and progression have developed from studies in
experimental carcinogenesis and are schematically rep-
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resented in Figure 1. This simplified diagram can be
used as intellectual framework to consider the stages
at which carcinogen-DNA adducts may play a role in
the multistage process ofcarcinogenesis. Assumingthat
these adducts lead to genetic lesions, including muta-
tions, tumor initiation and conversion are the stages
where our attention should be focused. The earliest
events in chemical carcinogenesis, i.e., tumorinitiation,
are considered to include exposure to the carcinogen,
transport ofthe carcinogen to the target cell, activation
to its ultimate carcinogenic metabolite if the agent is a
procarcinogen, and DNAdamageleadingtoaninherited
change and the preneoplastic "initiated" cell. Tumor
conversion is an updated version ofan old concept, i.e.,
benign tumors can convert to malignant tumors. Indi-
rect evidence for this view is based on the finding of
microinvasive carcinoma in putative preneoplastic le-
sions such as squamous metaplasia in the respiratory
tract and adenomas in the large intestine. Recent stud-
ies using the mouse skin carcinogenesis model suggest
that conversion of a benign tumor to a malignant one
requires another genetic event in that DNA-damaging
andmutagenicagents enhance thefrequency and hasten
the conversion of benign papillomas to squamous cell
carcinomas (3). Therefore, carcinogen-DNA adducts
may be important in both the early (tumor initiation)C. C. HARRIS
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FIGURE 1. Schematic representation of the multistage process of carcinogenesis. Examples of factors that may either enhance or inhibit
carcinogenesis are taken from studies of experimental carcinogenesis.
and later (tumor conversion) stages of carcinogenesis.
Because cancer is the result of complex interaction
between multiple environmental factors and both ac-
quired and inherited host factors (4), one should con-
sider carcinogen-DNA adducts as only one piece in the
puzzle. Examples ofother portions ofthe puzzle include
determinants of tumor promotion and progression. In
the skin carcinogenesis studies, wide variations in sus-
ceptibility to tumor-promoting agents have been ob-
served among animal species and among different inbred
strains of a single species (Table 1) (5). Epidemiological
studies suggest that tumor promotion may influence both
tumorincidence andlatencyperiod inhumans (6). There
is also increasing amount of data which suggests that
chemical carcinogens may cause both direct DNA dam-
age, i.e., carcinogen-DNA adducts, and indirect DNA
damage by causing formation of free radicals and su-
peroxides that react with DNA and cause molecular
lesions, e.g., thymine glycol (7). Carcinogens can dam-
agemembranes andinitiate the arachidonic acid cascade
and the release oflipid peroxidation aldehydes, such as
4-hydroxyalkenals (8) thatbind to DNA. Phthalates and
hypolipidemic drugs, including clofibrate, apparently
act through an indirect mechanism by causing prolif-
eration of peroxisomes and a subsequent increase in
superoxides (9). Measures ofindirect DNA damage are
needed, e.g., the development ofmonoclonal antibodies
to thymine glycol in DNA (10).
The carcinogenicity and mutagenicity ofchemicals may
be dependent on more than one metabolite. For ex-
Table 1. Sensitivity to skin carcinogenesis in different stocks and strains of mice.
Sensitivitya
Complete carcinogenesis Sencar > CD-1 > C57BL/6 ¢BALB/c > ICR/Ha Swiss > C3H
Two-stage carcinogenesis
(initiation-promotion) Sencar >> CD-1 > ICR/Ha Swiss BBALB/c > C57BL/6¢rC3H ¢r DBA/2
'Datarepresent sensitivities ofvarious mouse strains tobenzo(a)pyrene and 7,12-dimethylbenz(a)anthracene. Rankingrepresents asubjective
view because dose-response data were not available for all strains (5).
Progression
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ample, aldehydes are also produced in equimolar con-
centrations with alkyldiazonium ions during the
metabolism of N-nitrosamines. The effects of such al-
dehydes on normal human cells are being studied (11,12).
For example, formaldehyde inhibits DNA repair of O6-
methylguanine and potentiates the mutagenicity of an
alkylating agent, N-methyl-N-nitrosourea, in normal
human fibroblasts. Because formaldehyde alone also
causes mutations in human cells, we propose that for-
maldehyde may cause genotoxicity by adualmechanism
of directly damaging DNA and also inhibiting repair of
mutagenic and carcinogenic DNA lesions caused by other
chemical and physical carcinogens.
Determinants of Carcinogen-DNA
Levels
The amount ofcarcinogen-DNA adducts detected at
any time point is dependent on several dynamic factors,
including carcinogen exposure, the metabolic balance
between carcinogen activation and deactivation, and
DNA repair rates (Fig. 2). Procarcinogens from several
chemical classes are enzymatically activated to metab-
olitesthat bind to DNAincultured humantissues (Table
2), and the predominant adducts are similar to those
found in experimental animals in which the chemical is
known to be carcinogenic. In humans, both wide (50- to
150-fold) interindividual variations in the amounts of
adducts formed from several chemical classes of pro-
carcinogens metabolized in cultured human tissues (Ta-
ble 3) (13) and also severalfold variation in rates of
excision DNA repair (14) have been observed. The ac-
tivities of DNA repair enzymes may vary, too. For ex-
ample, the activity of 06-alkylguanine-DNA
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FIGURE 2. Major determinants of amounts of carcinogen-DNA
adducts.
alkyltransferase is generally 10-fold higher in human
tissues when compared to the corresponding rat tissue,
and a wider interindividual variation is found in the
outbred human species than among individual inbred
rats (Table 4) (15,16). We must also be aware of the
complexities inherent in measuring carcinogen-DNA
adducts in the intact animal. When considering the dy-
namics ofcell renewal and loss in the tissues, the prob-
lem of quantitative extrapolation between an individual's
carcinogen exposure and the detected amount of car-
cinogen-DNA adducts becomes even more obvious.
Measures ofputative DNA repair products are being
developed. Followingthe lead ofWogan and co-workers
(17), who assayed aflatoxin B,-modified guanine in the
urine of rats exposed to aflatoxin B1, Autrup et al. (18)
detected these adducts in urine of Africans who were
ingesting mycotoxin-contaminated food. Indirect DNA
Table 2. Chemical carcinogens activated to form DNA adducts by cultured human bronchus,
colon, esophagus, pancreatic duct, and bladder.'
Pancreatic
Carcinogen Bronchus Colon Esophagus duct Bladder
Polynuclear aromatic hydrocarbons
Benzo(a)pyrene +a + + + +
7,12-Dimethylbenz(a)anthracene + + + + 0
3-Methylcholanthrene + + + 0 0
Dibenz(a,h)anthracene + + + 0 0
N-Nitrosamines
Nitrosodimethylamine + + + + 0
Nitrosodiethylamine + + + 0 0
Nitrosopyrrolidine + + - 0 0
Nitrosopiperidine + - - 0 0
Dinitrosopiperazine + + 0 0 0
Mycotoxins
AflatoxinB1 + + + 0 +
T-2 Toxin 0 0 + 0 0
Hydrazines
1,2-Dimethylhydrazine + + + 0 0
Aromatic amines
2-Acetylaminofluorene + 0 + 0 +
Trp-P-1 (3-amino-1,4-dimethyl-
5H-pyrido[4,3-b]indole) 0 + 0 0 0
aKey: (+) detection of carcinogen binding to DNA; (-) binding not detected; (0) not tested.
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Table 3. Interindividual variation in carcinogen binding to DNA
in cultured human tissues.a
Fold variation in carcinogen binding'
Tissue BP AFB, DMNA 1,2-DMH AAF DMBA
Esophagus 99 70 90
Trachea 6
Bronchus 75 120 60 10 18 50
Peripheral lung 3
Liver 12
Duodenum 31
Colon 130 150 145 80
Bladder 68 127 114
Endometrium 70
aThe highest variation among people reported for carcinogen-DNA binding in cultured human tissues (38).
bKey: BP, benzo(ajpyrene; AFBj, aflatoxin B1; DMNA, N-nitrosodimethylamine; 1,2-DMN, 1,2-dimethylhydrazine; AAF, 2-acetylamino-
fluorene; DMBA, 7,12-dimethylbenz(a)anthracene.
Table 4. Activities of 06-alkylguanine-DNA alkyltransferase in extracts from human and rat tissues.
06-Alkylguanine-DNA alkyltransferase activity, fmole/mgA
Human Rat
Mean Range No. of samples Meanb No. of samples
Liver 873 411-1795 5 115 4
Colon 261 135-413 10 21 4
Esophagus 217 184-283 3 29 4
Lung 122 41-194 13 54 4
Brain 76 37-122 5 < 15 4
aAlkylguanine transalkylase activitywas assayed by followingthe loss ofO6-methylguanine from3H-methylated DNAusingspecific antibodies
for O6-methylguanine or by quantitation of the methylated purine content by high performance liquid chromatography.
bThe range of activities in extracts from rat tissues varied less than 20%.
damage caused by superoxides can also be assessed in
urine by measuring thymine glycol formed in experi-
mental animals, e.g., after ionizing radiation (19). This
noninvasive technique may be useful in monitoring in-
dividual animals and eventually humans to determine if
this and other assays will predict exposure and/or
susceptibility.
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FIGURE 3. Human tissues in biomedical research. In vitro models
provide a link between studies using animal models and clinical
investigations.
Animal models provide invaluable information in
studies of carcinogenesis. Extrapolation of this infor-
mation from experimental animals to humans remains,
however, an problematic endeavor. Most scientists con-
sider the qualitative extrapolation to be accurate, i.e.,
a chemical that is carcinogenic in experimental animals
is likely to be carcinogenic in humans. The current de-
bate centers on the question of quantitative extrapo-
lation, i.e., the carcinogenic potency of a chemical. In
my opinion, this question will not be resolved by math-
ematical modeling but will require both a better un-
derstanding of the mechanisms of carcinogenesis
obtained from comparative studies by using the strat-
egy schematically illustrated in Figure 3. For example,
responses to carcinogens, tumor promoters, anticarcin-
ogens, etc., can be compared in tissues and cells main-
tained in the same controlled in vitro setting from hu-
mans and experimental animals. Over the last decade,
Table 5. Physical and immunological methods to identify
carcinogen-DNA adducts in human biological specimens.
Assays Estimate ofsensitivity
Enzyme radioimmunoassay 1 adduct per 10-8 bases
3P postlabeling and nucleotide
chromatography 1 adduct per 10710 bases
Synchronous fluorescence
spectrophotometry 1 adduct per 107 bases
Radioimmunoassay 1 adduct per 105 bases
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a large volume of experimental data has accumulated
using this approach (2).
Laboratory observations indicating that the meta-
bolic pathways of carcinogen activation and the pre-
dominant carcinogen-DNA adducts are similar among
most animal species both strengthen our confidence in
the qualitative extrapolation and suggest approaches to
directly measure molecular lesions considered to be im-
portant in human carcinogenesis. For example, both
immunological and physical techniques have recently
been developed to measure adducts in macromolecules,
including DNA isolated from carcinogen-exposed tis-
sues and cells (Table 5). One ofthe advantages ofthese
approaches is that they can be specific for both carcin-
ogenic agent and target cell type. Antisera, both mon-
oclonal and polyclonal, have been produced to a variety
ofspecific carcinogen-DNA adducts (20,21) and also to
DNAlesions caused by ionizingradiation, e.g., thymine
glycol (10), and ultraviolet radiation, e.g., thymidine
dimers (22,23). Highly sensitive enzyme immunoassays
have been developed to measure adducts in isolated
DNA from carcinogen-exposed tissues (24) and in his-
tologicaland cytological preparations (25-27). These im-
munoassays gain their specificity from the antibody-
antigen reaction which is geometrically amplified by an
enzyme conjugated to one ofthe immunoreactants, usu-
ally the antibody (Fig. 4). P32-Nucleotide postlabeling
and thin-layer chromatography (28), high pressure li-
quidchromatography ofDNAhydrolysates (29-31), and
synchronous fluorescence spectrophotometry (32) of
carcinogen-DNA adducts are physical methods that also
show promise. The latter technique is obviously useful
only for those carcinogens that fluorescence, e.g., po-
lynuclear aromatic hydrocarbons. These physical tech-
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FIGURE 4. Two principles of enzyme radioimmunoassays are spec-
ificity and amplification.
niques complement both one another and also the
measurement of adducts by enzyme immunoassays.
In preliminary studies (33,34), benzo(a)pyrene diol
epoxide-DNA adducts havebeendetected intissue and
peripheral blood samples from people exposed to
benzo(a)pyrene. There is wide interindividual variation
in the amounts of adducts measured, which may be a
reflection of differences in environmental exposure to
benzo(a)pyrene, ratio ofmetabolic activation and deac-
tivation, and DNA repair rates. Ongoinginvestigations
are assessing the contribution of each of these factors
in determining the amounts ofadducts. Although there
is a positive association between adduct levels and tu-
mor-initiating potency in many, but not all, studies us-
ing animal models (35), it is not known whether such
an association exists in human carcinogenesis.
Future Research Needs
First, we need to validate current methodology to
detect carcinogen-DNA adducts as to specificity, sen-
sitivity, interlaboratory reproducibility, etc. This will
require a coordinated effort similar to that developed
for validating other "short-term" assays. Because hu-
mans are usually exposed to a variety of chemical car-
cinogens at poorly defined doses and timeframes, the
amount of adduct measured at any one time will be a
composite ofpast exposure and the other determinants
of carcinogen-DNA adducts discussed above. In addi-
tion, methods are needed to detect specific adducts in
complex mixtures of carcinogen-DNA adducts. Both
the immunological and physical assays have this poten-
tial. Mixtures of antibodies to an array of adducts can
be used as an initial screen. The physical assays, syn-
chronous fluorescence spectrophotometry and 32P-post-
labeling and nucleotide chromatography, may be
especially suited for analysis of a mixture ofadducts in
a biological sample. "Fingerprints" of computer-gen-
erated contour maps of spectra obtained by three-di-
mensional synchronous fluorescence spectrophotometry
and two-dimensional autoradiograms of chromato-
graphed 32P-labeled nucleotides may be stored in com-
puter libraries similar to those established for data
obtained by mass spectroscopy and by nucleotide and
amino acid sequencing techniques. The Laboratory of
Human Carcinogenesis, DCE, National Cancer Insti-
tute, has initiated such a library of contour maps gen-
eratedbysynchronous fluorescence spectrophotometry.
We plan to obtain spectral data in future ofcarcinogen-
DNA adducts, carcinogen-nucleotide adducts, carcin-
ogen-base adducts, and carcinogens and their metab-
olites that willbe available inthe future toinvestigators
worldwide through currently available telecommuni-
cation links.
Current dogma has directed our efforts to measuring
adducts formed by the direct interaction between the
activated carcinogen metabolite(s). However, as dis-
cussed above, carcinogens may also exert their onco-
genic effects via indirect damage to macromolecules,
such as carcinogen-induced formation of superoxides
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which cause DNAdamage, includingthymineglycoland
other altered nucleic acid structures. This induction of
the prooxidant state, i.e., increased concentrations of
active oxygen, organic peroxides and radicals, may also
be of importance in tumor promotion (7). Additional
research is needed in this important area.
Second, new methodologies to measure carcinogen-
DNA adducts are still needed. Ultratrace mass spectral
technique is one that is currently being developed (36).
Weshould alsoconsiderthepotentialvalueofmeasuring
adducts at different levels ofbiologicalorganization (Ta-
ble 6). Immunocytochemistry and immunofluorescent
microscopy should bevaluable techniquesformeasuring
adducts in individual cells. Detection of adducts and
DNA damage in specific genes, e.g., oncogenes, and
DNA sequences, e.g., transcriptional control regions
(37), is a research goal that could strengthen the as-
sociation amonggenerearrangements, point mutations,
and activation of oncogenes. Because the putative me-
chanistic link between carcinogen-DNA adducts and
tumor initiation is not well understood, research in this
area remains of fundamental importance.
Third, additional studies are needed to evaluate car-
cinogen-DNA adducts as qualitative and quantitative
indicators ofdisease (Table 7). Animal models will con-
tinue to be essential for these studies. Monitoring of
individual animals and relating the results ofthe assays
with the tumor incidence, type, location, and latency
period in each animal is an area of high priority. Mea-
Table 6. Location of carcinogen-DNA adduct localization
at different levels of biological organization.
Level Location
Tissue and cell Target tissue and cell
"Indicator" cells
Nucleus and mitochondria
Nucleus Matrix
Nucleosome-linker and core
Replicon
DNA Genomic
Repetitive sequences
Gene
Intragene
Table 7. Research goal: evaluate carcinogen-DNA adducts as
indicators of disease risk.
Model type Research goal
Animal models Adduct levels in indicator vs. target cells
DNA repair rates ofcarcinogen-DNA
adducts
Carcinogen exposure vs. adduct levels
Adduct levels in individual animals
Relationship between adduct levels and
tumor type, location, incidence, and
latency period
In vitro models Relationship between adduct levels and
endpoints ofmutagenicity and
carcinogenicity
Interspecies comparisons between exper-
imental animal and human cells
Table 8. Potential markers for early biological or biochemical
responses to carcinogens in humans.
Types of markers Examples
Chromosomal Sister chromatid exchanges, chromo-
abnormalities somal breaks, translocations, and ab-
errations (peripheral lymphocytes
and target tissues)
Markers for point HGPRT and thymidine kinase in pe-
mutations ripheral lymphocytes
Markers for altered Ectopic hormones, cytokeratins, em-
gene expression bryonic proteins
Reproductive toxicity Sperm abnormalities: morphology or
density
Membrane changes Monoclonal antibodies to antigens on
tumor cells
surements ofcarcinogen-DNA adducts should be incor-
porated into a battery of other assays (Table 8) (1,2).
In vitro models will also be needed for investigations
comparing response in tissues and cells from humans to
those of experimental animals (Fig. 3).
Fourth, biochemicalepidemiological studiesareyield-
ingimportantinformation, includingpreliminaryresults
indicating that carcinogen-DNA adducts can be de-
tected inpeople exposed to carcinogens. More attention
can now be directed at more complex experimental de-
signs, e.g., studyingthe adduct removalrates in people
who have ceased smoking tobacco. Cancer patients re-
ceiving chemotherapy are an example of a study pop-
ulation in which the dose and regimen of exposure to
DNA-damaging agents is well defined. It should be em-
phasized that (a) laboratory-epidemiological studies are
more complicated than those using animal models be-
cause of ethical, medical, and legal concerns and (b)
carcinogen-DNA adductsareprobablyrelatedtotumor
initiation and to perhaps tumor conversion, which are
only two stages in multistage carcinogenesis.
Fifth, theinvestigationsmentioned abovewillrequire
sustained and substantial financial support from pri-
vate, industrial, andgovernmental sources. Bothanimal
and clinical studies are intrinsically long-term in nature
and thus costly.
The comments of Drs. Kirsi Vahakangas and Dean Mann and the
secretarial aid of Norma Paige are appreciated.
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